An open-label, randomized, multi-center phase 2 study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2-breast cancer (MBC) with an ESR1 mutation

Category Primary study
JournalCancer Research
Year 2019
This article has no abstract
Epistemonikos ID: 667bcedba46b4067b4df8412f384d727e8ac2d3c
First added on: Feb 10, 2025